#USA #New York #Levi & Korsinsky #Securities Class Action #PROCEPT BioRobotics

Recent Developments in PROCEPT BioRobotics Corporation Lawsuit

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is currently facing a significant securities class action lawsuit led by Levi & Korsinsky, LLP. This legal action has been initiated on behalf of shareholders who acquired securities between February 28, 2024, and February 25, 2026. The essence of this lawsuit revolves around allegations that the company misrepresented key operational metrics, leading to inflated stock prices that ultimately dropped sharply after crucial disclosures.

Details of the Class Action Lawsuit

The alleged discrepancies stem from claims that the company’s reporting on handpiece sales, recurring revenue, and customer inventory levels were either misleading or incomplete. These reported figures supposedly misrepresented the demand and efficiency of their products. When Procept disclosed the actual data regarding procedures involving their products on February 25, 2026, it revealed that handpiece sales had been overstated, exceeding actual procedures by a notable percentage. This revelation precipitated a dramatic drop in stock value, from a high of roughly $100.00 down to around $25.00, equating to more than a 75% decline.

Shareholders who acquired their shares within the specified class period and experienced losses may qualify as plaintiffs in this case. It is worth noting that investors do not need to be appointed as lead plaintiffs to participate in any potential recovery, which provides an important opportunity for many involved.

Legal Insights

Joseph E. Levi, leading the charge on this lawsuit, noted, "When companies fail to disclose material information, shareholders may suffer significant losses. Our complaint highlights that PRCT investors were under a false impression of what they were purchasing, based on misleading sales and inventory practices which artificially inflated stock prices."

The courtroom location for this case is in the United States District Court for the Northern District of California, specifically within the San Jose Division. Investors interested in participating should take action promptly, as the deadline for moving for lead plaintiff status is set for September 22, 2026.

FAQs for Affected Shareholders

1. What should I do if I purchased PRCT shares during the Class Period? If you bought shares between February 28, 2024, and February 25, 2026, you may be eligible for compensation if you suffered a financial loss.
2. What if I already sold my shares? You are still eligible to recover losses based on your acquisition date, irrespective of whether you currently hold the shares or not.
3. Will I need to appear in court? Generally, no. Most class members will not need to testify or appear in court; claims are often submitted through straightforward forms if a settlement occurs.
4. What costs should I expect? It's crucial to note that, for securities class actions, there are typically no upfront fees. Legal costs are usually contingent on successful recovery, following court approval.

Conclusion

For shareholders of PROCEPT BioRobotics Corporation affected by this alleged misconduct, timely action is essential. If you believe you are eligible, contact Levi & Korsinsky, LLP to navigate your options. With nearly two decades of experience in handling securities litigation and securing substantial recoveries for investors, the firm is well-equipped to guide you through this legal process. Investors must stay informed and understand their rights in instances of corporate misrepresentation, ensuring they seek justice for their losses.

For further information or assistance, reach out to Levi & Korsinsky at their New York office or visit their website for more details on participation in this class action lawsuit.